Amivantamab – July 2026

  • Solution for subcutaneous injection 1600 mg in 10 mL
  • Solution for subcutaneous injection 2240 mg in 14 mL
  • Solution for subcutaneous injection 2400 mg in 15 mL
  • Solution for subcutaneous injection 3520 mg in 22 mL

  • Brand names:
    • Rybrevant SC®
  • Pharmaceutical Company:
    • JANSSEN-CILAG PTY LTD
  • Condition/Indication: Non-small cell lung cancer (NSCLC)
  • Meeting Date: July 2026

Last updated
13 November 2026